Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 1–2, pp 14–19 | Cite as

Schwerpunkt Amyloidose

Prognose und Therapie der AL-Amyloidose

  • Timon HansenEmail author
schwerpunkt
  • 64 Downloads

Trotz gewisser Fortschritte in der Therapie der AL-Amyloidose ist die Prognose in vielen Fällen immer noch ungünstig. Grund dafür ist, dass die Diagnose häufig erst dann gestellt wird, wenn schon ausgedehnte Organschäden bestehen, die meist irreversibel sind. Dies soll sich zukünftig jedoch ändern.

Literatur

  1. 1.
    Kumar S et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95CrossRefGoogle Scholar
  2. 2.
    Palladini G et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–32CrossRefGoogle Scholar
  3. 3.
    Palladini G et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–9CrossRefGoogle Scholar
  4. 4.
    Bochtler T et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33(12):1371–8CrossRefGoogle Scholar
  5. 5.
    Muchtar E et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017;31(7):1562–9CrossRefGoogle Scholar
  6. 6.
    Dittrich T et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017;130(5):632–42CrossRefGoogle Scholar
  7. 7.
    Milani P et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130(5):625–31CrossRefGoogle Scholar
  8. 8.
    Sidana S et al. The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. Leukemia. 2018;32(5):1243–6CrossRefGoogle Scholar
  9. 9.
    Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128(2):159–68CrossRefGoogle Scholar
  10. 10.
    Kaufman GP et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130(7):900–2CrossRefGoogle Scholar
  11. 11.
    Hegenbart U et al. EGCG Treatment In Patients With Cardiac AL Amyloidosis: First Results Of A Randomized And Placebo-Controlled Clinical Trial of Germany. ISA. 2018;Abstr e278Google Scholar
  12. 12.
    Muchtar E et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111–9CrossRefGoogle Scholar
  13. 13.
    Kastritis E et al. A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood. 2016;128(22):646Google Scholar
  14. 14.
    Palladini G et al. Treatment of AL Amyloidosis with Bortezomib Combined with Alkylating Agents: Results From a Prospective Series of Unselected Patients. Blood 2011;118(21):3977Google Scholar
  15. 15.
    Palladini G et al. First Line Therapy With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) In Patients With AL Amyloidosis and Potentially Reversible Contraindications To Autologous Stem Cell Transplant. Blood 2013 122(21):1985Google Scholar
  16. 16.
    Palladini G et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–5CrossRefGoogle Scholar
  17. 17.
    Hegenbart U et al. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica. 2017;102(8):1424–31CrossRefGoogle Scholar
  18. 18.
    Kumar SK et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119(21):4860–7CrossRefGoogle Scholar
  19. 19.
    Kastritis E et al. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015;90(4):E60–5CrossRefGoogle Scholar
  20. 20.
    Mahmood S et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol. 2014;166(6):842–8CrossRefGoogle Scholar
  21. 21.
    Palladini G et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129(15):2120–3CrossRefGoogle Scholar
  22. 22.
    Kimmich C et al. Daratumumab monotherapy in 54 heavily pretreated patients with advanced systemic AL amyloidosis. 2018. The XVIth International Symposium on Amyloidosis. Oral Presentation #37Google Scholar
  23. 23.
    Gertz MA et al. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J Clin Oncol. 2016;34(10):1097–103CrossRefGoogle Scholar
  24. 24.
    Edwards CV et al. Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid. 2017;24(sup1):58–9CrossRefGoogle Scholar
  25. 25.
    Richards DB et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci Transl Med. 2018;10(422). pii: eaan3128.CrossRefGoogle Scholar
  26. 26.
    Richards DB et al. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med. 2015;373(12):1106–14CrossRefGoogle Scholar
  27. 27.
    Lacy MQ et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant. 2008;27(8):823–9CrossRefGoogle Scholar
  28. 28.
    Kristen AV et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J Heart Lung Transplant. 2018;37(5):611–8CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Hämatologisch-Onkologische Praxis Altona (HOPA) MVZ GmbHHamburgDeutschland

Personalised recommendations